Cargando…

Lipid–Polymer Hybrid Nanoparticle-Based Combination Treatment with Cisplatin and EGFR/HER2 Receptor-Targeting Afatinib to Enhance the Treatment of Nasopharyngeal Carcinoma

PURPOSE: Nasopharyngeal carcinoma (NPC) is one of the most prevalent carcinomas among the Cantonese population of South China and Southeast Asia (responsible for 8% of all cancers in China alone). Although concurrent platinum-based chemotherapy and radiotherapy have been successful, metastatic NPC r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Dehui, Li, Chao, Huang, Yongwang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044085/ https://www.ncbi.nlm.nih.gov/pubmed/33859480 http://dx.doi.org/10.2147/OTT.S286813

Ejemplares similares

Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells
por: Huang, Fangling, et al.
Publicado: (2019)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma
por: Xue, Cong, et al.
Publicado: (2016)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
por: Harvey, R Donald, et al.
Publicado: (2020)

Ribociclib Hybrid Lipid–Polymer Nanoparticle Preparation and Characterization for Cancer Treatment
por: Al-Shdefat, Ramadan, et al.
Publicado: (2023)

Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series
por: Li, Shih-Hong, et al.
Publicado: (2015)

Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
por: Khan, Muhammad Muzamil, et al.
Publicado: (2019)

Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles
por: Fu, Qingxia, et al.
Publicado: (2020)

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
por: Bahleda, Rastislav, et al.
Publicado: (2018)

Combination Chemotherapy of Lung Cancer – Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid–Polymer Hybrid Nanoparticles
por: Wu, Ruifeng, et al.
Publicado: (2020)

Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer
por: Wang, Qi, et al.
Publicado: (2017)

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
por: De Pauw, Ines, et al.
Publicado: (2018)

Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
por: Harada, Yohei, et al.
Publicado: (2023)

Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells
por: Li, Jun, et al.
Publicado: (2017)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Co-Delivery of Curcumin and Cisplatin to Enhance Cytotoxicity of Cisplatin Using Lipid-Chitosan Hybrid Nanoparticles
por: Khan, Muhammad Muzamil, et al.
Publicado: (2020)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
por: Xu, Huanhuan, et al.
Publicado: (2021)

Optimized Polyethylene Glycolylated Polymer–Lipid Hybrid Nanoparticles as a Potential Breast Cancer Treatment
por: Massadeh, Salam, et al.
Publicado: (2020)

Transferrin-Decorated Protein-Lipid Hybrid Nanoparticle Efficiently Delivers Cisplatin and Docetaxel for Targeted Lung Cancer Treatment
por: Mao, Kaiping, et al.
Publicado: (2021)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma
por: Yamanaka, Yumie, et al.
Publicado: (2019)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2019)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report
por: Cai, Yangyang, et al.
Publicado: (2019)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

Lipid-polymer hybrid nanoparticle with cell-distinct drug release for treatment of stemness-derived resistant tumor
por: Shen, Shiyang, et al.
Publicado: (2023)

Chinese Medicine Treatment for Afatinib-Induced Paronychia
por: Yang, Pei-Yuu, et al.
Publicado: (2017)

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)

Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells
por: Yoshioka, Takahiro, et al.
Publicado: (2019)

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
por: Wu, Yi-Long, et al.
Publicado: (2018)

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
por: Longo, Vito, et al.
Publicado: (2021)

Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
por: Brückl, Wolfgang M., et al.
Publicado: (2021)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
por: Kang, Liping, et al.
Publicado: (2023)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
por: Wei, Yang, et al.
Publicado: (2021)

Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
por: Longton, Eleonore, et al.
Publicado: (2018)

Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment
por: Wu, Bo, et al.
Publicado: (2017)

Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report
por: Zhang, Ping, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6r9ridh22rtgo0mismfvg62chn